These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 9086151

  • 1. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

  • 2. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y, Choi JW, Kim HJ, Eddouzi J, Kim SC, Ju W, Kim YH, Kim HJ.
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
    Evans C, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, Wagner H, Lipford GB.
    Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.
    Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S.
    Cancer Res; 1997 Nov 01; 57(21):4855-61. PubMed ID: 9354449
    [Abstract] [Full Text] [Related]

  • 11. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M, Albert Einstein Cervix Dysplasia Clinical Consortium.
    Cancer Epidemiol Biomarkers Prev; 2002 May 01; 11(5):483-8. PubMed ID: 12010863
    [Abstract] [Full Text] [Related]

  • 12. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J.
    Clin Cancer Res; 2000 Sep 01; 6(9):3406-16. PubMed ID: 10999722
    [Abstract] [Full Text] [Related]

  • 13. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.
    Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB.
    Clin Diagn Lab Immunol; 1999 Jul 01; 6(4):494-8. PubMed ID: 10391849
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    J Virol; 2009 Jul 01; 83(13):6779-89. PubMed ID: 19386711
    [Abstract] [Full Text] [Related]

  • 16. Serologic response in human papillomavirus-associated invasive cervical cancer.
    Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Muñoz N, Shah KV.
    Int J Cancer; 1993 Nov 11; 55(5):780-4. PubMed ID: 8244575
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Distribution of human papillomavirus 16 E6/E7 variants in cervical cancer and intraepithelial neoplasia in Chinese women.
    Ding T, Wang X, Ye F, Cheng X, Lu W, Xie X.
    Int J Gynecol Cancer; 2010 Nov 11; 20(8):1391-8. PubMed ID: 21051983
    [Abstract] [Full Text] [Related]

  • 19. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK, Liu SJ, Cheung TH, Yeo W, Ngai SM, Cheung JL, Chong P, Man S.
    Clin Vaccine Immunol; 2010 Sep 11; 17(9):1315-21. PubMed ID: 20668141
    [Abstract] [Full Text] [Related]

  • 20. Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN).
    Mathur SP, Mathur RS, Rust PF, Young RC.
    Am J Reprod Immunol; 2001 Oct 11; 46(4):280-7. PubMed ID: 11642677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.